NCT07924553
Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes
StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Proportion of the participants achieving time in range (TIR)>70 and time below range (TBR)<4% (TIMES-EFFICACY)
Timeframe: From baseline to 16 weeks
Volume of non-calcified coronary artery plaque (TIMES-CV)
Timeframe: From baseline to 52 weeks
Secondary (11)
Level of HbA1c
Volume of coronary atherosclerotic plaque
Thickness of carotid intima-media
Time in range (TIR)
Time above range (TAR)
Show 6 moreShow less
Time below range (TBR)
Covariation (CV)
Level of triglyceride (TG)
Level of total cholesterol (TC)
Level of low-density cholesterol (LDL-C)
Level of high-density cholesterol (HDL-C)
Arms and interventions
mazdutide groupExperimental
Participants in the treatment group will receive mazdutide by subcutaneous injection once weekly. The dose will be escalated stepwise according to a pre-defined regimen from a safe starting dose to an effective maintenance dose (from 2 mg to 4 mg) over several weeks, with dose reduction permitted if needed.
placebo groupPlacebo comparator
Participants in the control group will receive a placebo matched to mazdutide in appearance, packaging, and mode of administration, by subcutaneous injection once weekly.
Drugs: Mazdutide, Placbo